India Gestational Trophoblastic Disease Market Size & Outlook, 2026-2034

India Gestational Trophoblastic Disease Market Insights

Reed Intelligence analysis indicates that the India Gestational Trophoblastic Disease Market size, valued at USD 27.73 Million in 2025, is expected to expand to USD 51.38 Million by 2034.
The India market is forecasted to expand at a CAGR of 7.15% spanning 2026–2034.
Hydatidiform Mole held the leading position among Type segments in 2025, based on market size.
Choriocarcinoma is projected to post the fastest growth rate, sustaining its position as the most attractive Type segment during the forecast horizon.

Other Key Findings

In 2025, India accounted for 3.56% of the global Gestational Trophoblastic Disease Market size.
By 2034, United States is expected to lead the global Gestational Trophoblastic Disease Market in terms of market size.
Within Asia Pacific, China is projected to dominate the regional Gestational Trophoblastic Disease Market size by 2034.
China is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 102.98 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 27.73 Million
Market Size In 2034	USD 51.38 Million
Largest segment	Hydatidiform Mole
Units	Revenue in USD Million
CAGR	7.15% (2026-2034)
Segmnetation Covered
Type	Hydatidiform Mole Choriocarcinoma Placental Site Trophoblastic Tumor
Treatment	Chemotherapy Immunotherapy Surgery
End-Use	Hospitals Specialty Clinics Research Institutes
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

India Gestational Trophoblastic Disease Market Type 2026-2034 (USD Million)

Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hydatidiform Mole	XX.x	XX.x	XX.x	12.59	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Choriocarcinoma	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Placental Site Trophoblastic Tumor	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

India Gestational Trophoblastic Disease Market Treatment 2026-2034 (USD Million)

Treatment	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Chemotherapy	XX.x	XX.x	XX.x	13.21	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immunotherapy	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Surgery	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

India Gestational Trophoblastic Disease Market End-Use 2026-2034 (USD Million)

End-Use	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	15.03	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Research Institutes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.